The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Open accessAbstract
BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more. RESULTS: Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy. CONCLUSIONS: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab, a PD-1 inhibitor, in combination with ipilimumab, a CTLA-4 inhibitor, has shown favourable efficacy outcomes and manageable safety profiles across multiple tumour types.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [39]
In the citing paper
“First-line nivolumab + ipilimumab treatment also produced longer OS than chemotherapy in patients with advanced NSCLC10.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“First-line nivolumab + ipilimumab resulted in a longer duration of OS than chemotherapy in patients with metastatic NSCLC, irrespective of the PD-L1 expression10,28.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [10]
In the citing paper
“most notably the combination of pembrolizumab and axitinib (an inhibitor of vascular growth factor inhibitor) in renal cell carcinoma.15”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [15]
In the citing paper
“Until now, the FDA has approved the ipilimumab plus nivolumab for melanoma, RCC, MSI-H/dMMR colorectal cancer, HCC, PD-L1 positive NSCLC, and malignant pleural mesothelioma (Table 5) [132–138].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
In the citing paper
“Moreover, the data of CheckMate-214, CheckMate-227, and CheckMate-743 indicated the superior efficacy of ipilimumab plus nivolumab over the standard targeted therapy or chemotherapy [135–137].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Self-citationFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,003
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Zhou, K., Li, S., Zhao, Y., & Cheng, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127071 · Cited by 49
Updated Immunotherapy for Gastric Cancer
Narita, Y., & Muro, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072636 · Cited by 51
Focused ultrasound-assisted delivery of immunomodulating agents in brain cancer
Memari, E., Khan, D. S., Alkins, R. D., & Helfield, B. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.034 · Cited by 49
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
Tang, L.-B., Peng, Y., Chen, J., Li, J.-T., Zheng, M.-M., Lv, W., Lu, C., Wei, X., Cai, D.-X., Guo, Z. J., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01029-7 · Cited by 49
Шульгин, Б. В., Kosinsky, Y., Omelchenko, A. V., Chu, L., Mugundu, G. M., Aksenov, S., Pimentel, R., DeYulia, G., Kim, G., Peskov, K. V., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1748982 · Cited by 49
Silva, P. D., Aiello, M. M., Gu‐Trantien, C., Migliori, E., Willard-Gallo, K. E., & Solinas, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33415 · Cited by 49
Ferrara, R., Imbimbo, M., Malouf, R. S., Paget‐Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257.pub2 · Cited by 51
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
Siozopoulou, V., Domen, A., Zwaenepoel, K., Beeck, A. V., Smits, E., Pauwels, P., & Marcq, E. (2021) · Cancers · doi:10.3390/cancers13020360 · Cited by 49
Stares, M. D., Swan, A. M., Cumming, K., Ding, T.-E., Leach, J., Stratton, C., Thomson, F., Barrie, C., Maclennan, K., Campbell, S., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.734735 · Cited by 47
Sové, R. J., Verma, B. K., Wang, H., Ho, W. J., Yarchoan, M. M., & Popel, A. S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005414 · Cited by 50
Resistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 50
Gutierrez, M. E., Lam, W., Hellmann, M. D., Gubens, M. A., Aggarwal, C., Tan, D. S. W., Felip, E., Chiu, J. W. Y., Lee, J.-S., Yang, J. C.-H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02385-6 · Cited by 49
Self-citationElkrief, A., Waters, N. R., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N. D., Lumish, M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0498 · Cited by 48
Self-citationTheelen, W. S. M. E., de Jong, M. C., & Baas, P. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.015 · Cited by 50
Leighl, N. B., Redman, M. W., Rizvi, N. A., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Wade, J. L., Irvin, W., Reddy, S., Crawford, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002973 · Cited by 47
Self-citationHong, M. M. Y., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14061580 · Cited by 52
Chen, J., Li, S., Yao, Q., Du, N., Fu, X., Lou, Y., Wang, M., Mao, F., Mao, D., Khadaroo, P. A., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01933-5 · Cited by 47
Tumor mutational burden on cytological samples: A pilot study
Pepe, F., Pisapia, P., Gristina, V., Rocco, D., Micheli, M., Micheli, P., Iaccarino, A., Tufano, R., Gragnano, G., Russo, G., et al. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22400 · Cited by 47
Li, N., Wang, J., & Zhan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752643 · Cited by 50
Ma, Y., Xue, J., Zhao, Y., Zhang, Y., Huang, Y., Yang, Y., Fang, W., Guo, Y., Li, Q., Ge, X., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006654 · Cited by 47
Pellini, B., Madison, R. W., Childress, M. A., Miller, S. T., Gjoerup, O. V., Cheng, J. H., Huang, R. S. P., Krainock, M. R., Gupta, P., Zou, W., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1578 · Cited by 47
Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer
Le, X., Ferrarotto, R., Wise-Draper, T. M., & Gillison, M. L. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7590 · Cited by 47
de Ruijter, L. K., Hooiveld-Noeken, J. S., Giesen, D., Hooge, M. N. L., Kok, I. C., Brouwers, A. H., Elias, S. G., Nguyen, M. T. L., Lu, H., Gietema, J. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0453 · Cited by 47
The use of immunotherapy in older patients with advanced non-small cell lung cancer
Tagliamento, M., Frélaut, M., Baldini, C., Naigeon, M., Nencioni, A., Chaput, N., & Besse, B. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102394 · Cited by 48
Passiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 48
Frigola, J., Navarro, A., Carbonell, C., Callejo, A., Iranzo, P., Cedrés, S., Martínez‐Martí, A., Pardo, N., Gonzalez, N. S., Martinez, D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12891 · Cited by 47
Ruysscher, D. D., Ramalingam, S. S., Urbanic, J. J., Gerber, D. E., Tan, D. S. W., Cai, J., Li, A., & Peters, S. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.07.005 · Cited by 49
Self-citationRubio‐Infante, N., Ramírez‐Flores, Y. A., Castillo, E. C., Lozano, O., García‐Rivas, G., & Torre‐Amione, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.851032 · Cited by 48
Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases
Huang, R. S. P., Harries, L., Decker, B. J., Hiemenz, M., Murugesan, K., Creeden, J., Tolba, K. A., Stabile, L. P., Ramkissoon, S. H., Burns, T. F., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac094 · Cited by 47
Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung
Santos, E. S., & Rodríguez, E. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.06.002 · Cited by 46
Immunotherapy in NSCLC Patients with Brain Metastases
Buriolla, S., Pelizzari, G., Corvaja, C., Alberti, M., Targato, G., Bortolot, M., Torresan, S., Cortiula, F., Fasola, G., & Follador, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137068 · Cited by 47
Petroni, G., Pillozzi, S., & Antonuzzo, L. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3325 · Cited by 52
Shen, S., Hong, Y., Huang, J., Qu, X., Sooranna, S. R., Lu, S., Li, T. X., & Niu, B. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.08.001 · Cited by 46
Lieverse, R. I. Y., Limbergen, E. J. V., Oberije, C., Troost, E. G. C., Hadrup, S. R., Dingemans, A. C., Hendriks, L. E. L., Eckert, F., Hiley, C. T., Dooms, C., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07055-1 · Cited by 47
König, D., & Laubli, H. P. (2020) · Pharmacology · doi:10.1159/000509081 · Cited by 49
Pavan, A., Bragadin, A. B., Calvetti, L., Ferro, A., Zulato, E., Attili, I., Nardo, G., Maso, A. D., Frega, S., Menin, A. G., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-674 · Cited by 47
Ayers, K. L., Ma, M., Debussche, G., Corrigan, D., McCafferty, J., Lee, K., Newman, S., Zhou, X., Hirsch, F. R., Mack, P. C., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08194-9 · Cited by 47
Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
Xiong, W. G., Zhao, Y., Du, H., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704336 · Cited by 47
Current status of immunotherapy for non-small cell lung cancer
Yang, T., Xiong, Y., Zeng, Y., Wang, Y., Zeng, J., Liu, J., Xu, S., & Li, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989461 · Cited by 45
Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions
Ser, M. H., Webb, M., Sener, U. T., & Campian, J. L. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-23-34 · Cited by 51
Chen, B., Yao, W., Li, X., Lin, G., Chu, Q., Liu, H., Du, Y., Lin, J., Duan, H., Wang, H., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02519-0 · Cited by 43
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 49
Yan, X., Tian, X., Wu, Z., & Han, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01671 · Cited by 45
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
Tfayli, A., Assaad, M. A., Fakhri, G. B., Akel, R., Atwi, H., Ghanem, H., Karak, F. E., Farhat, F. S., rabi, K. A., Sfeir, P. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3456 · Cited by 45
Pradhan, M., Chocry, M., Gibbons, D. L., Sepesi, B., & Cascone, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-573 · Cited by 44
Kleef, R., Nagy, R., Baierl, A., Bacher, V., Bojar, H., McKee, D. L., Moss, R. W., Thoennissen, N. H., Szász, A. M., & Bakács, T. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02751-0 · Cited by 46
Nadler, E., Arondekar, B. V., Aguilar, K. M., Zhou, J., Chang, J., Zhang, X., & Pawar, V. S. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03414-4 · Cited by 48
Hou, J., Wang, Y., Shi, L., Chen, Y., Xu, C., Saeedi, A., Pan, K., Bohat, R., Egan, N. A., McKenzie, J. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001819 · Cited by 46
Rojas, F. R., Hernandez, S. D., Lazcano, R., Laberiano-Fernández, C., & Parra, E. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889886 · Cited by 45
Shaikh, F. Y., White, J. R., Gills, J. J., Hakozaki, T., Richard, C., Routy, B., Okuma, Y., Usyk, M., Pandey, A., Weber, J. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4834 · Cited by 44
Voronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K. V., Sekacheva, M. I., Materenchuk, M. Y., Bunyatyan, N. D., & Lebedeva, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035884 · Cited by 47
Zhang, Z., Pan, Q., Lu, M., & Zhao, B. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102156 · Cited by 46
Palermo, B., Franzese, O., Frisullo, G., D’Ambrosio, L., Panetta, M., Campo, G., D’Andrea, D., Sperduti, I., Nicola, F. D., Goeman, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02846-3 · Cited by 46
Prognostic and predictive biomarkers in non-small cell lung carcinoma
Odintsov, I., & Sholl, L. M. (2023) · Pathology · doi:10.1016/j.pathol.2023.11.006 · Cited by 47
Zhao, Y., Chen, G., Li, X., Wu, J., Chang, B., Hu, S., Yang, S., Xu, T. S., Liu, Y., Wang, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101470 · Cited by 46
Sharma, A., Alexander, G., Chu, J. H., Markopoulos, A., Maloul, G., Ayub, M. T., Fidler, M. J., & Okwuosa, T. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032620 · Cited by 49
Zhou, Y., Zhang, Y., Guo, G., Cai, X., Yu, H., Cai, Y., Zhang, B., Hong, S., & Zhang, L. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.14 · Cited by 43
Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy
García-Fernández, C., Fornaguera, C., & Borrós, S. (2020) · Cancers · doi:10.3390/cancers12061609 · Cited by 44
Association between tumor mutation burden and immune infiltration in ovarian cancer
Fan, S., Gao, X., Qin, Q., Li, H., Yuan, Z., & Zhao, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107126 · Cited by 46
The promise of bispecific antibodies: Clinical applications and challenges
Lim, S. M., Pyo, K., Soo, R. A., & Cho, B. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102240 · Cited by 45
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
Leighl, N. B., Laurie, S. A., Goss, G. D., Hughes, B. G. M., Stockler, M. R., Tsao, M., Hwang, D. M., Joubert, P., Kulkarni, S., Blais, N., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.023 · Cited by 47
Liu, S., Gao, W., Ning, Y., Zou, X., Zhang, W., Zeng, L., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908173 · Cited by 46
Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival
Miah, A., Tinoco, G., Zhao, S., Wei, L., Johns, A. C., Patel, S. P., Li, M., Grogan, M. M., Lopez, G., Husain, M., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04340-3 · Cited by 43
Role Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer
Zhou, W., Lim, A., Edderkaoui, M., Osipov, A., Wu, H., Wang, Q., & Pandol, S. J. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83586 · Cited by 49
Biomarkers for immunotherapy resistance in non-small cell lung cancer
Rother, C., John, T., & Wong, A. N. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1489977 · Cited by 46
Burgers, F. H., van der Mijn, J. C., Seijkens, T. T. P., Jedema, I., Bex, A., & Haanen, J. B. A. G. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00983-w · Cited by 49
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 48
Puri, S., & Shafique, M. R. (2020) · Drugs in Context · doi:10.7573/dic.2019-9-2 · Cited by 44
Friedlaender, A., Nouspikel, T., Christinat, Y., Ho, L. K. F., McKee, T., & Addeo, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00142 · Cited by 44
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
Jia, Y., Liu, L., & Shan, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3735 · Cited by 43
Hu, H., She, L., Liao, M., Shi, Y., Yao, L., Ding, D., Zhu, Y., Zeng, S., Carbone, D. P., & Huang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01649 · Cited by 43
Reck, M., Ciuleanu, T., Lee, J.-S., Schenker, M., Audigier-Valette, C., Żurawski, B. A., Linardou, H., Otterson, G. A., Salman, P., Nishio, M., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.019 · Cited by 43
Self-citationWhat Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 47
Yu, Y., Wang, S., Su, N., Pan, S., Tu, B., Zhao, J., Shen, Y., Qiu, Q., Liu, X., Luan, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906824 · Cited by 43
Gridelli, C., Peters, S., Mok, T. S. K., Forde, P. M., Reck, M., Attili, I., & de Marinis, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100355 · Cited by 41
Self-citationPrecision medicine and the fragmentation of solidarity (and justice)
Fleck, L. M. (2022) · Medicine Health Care and Philosophy · doi:10.1007/s11019-022-10067-2 · Cited by 42
Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?
Putzu, C., Canova, S., Paliogiannis, P., Lobrano, R., Sala, L., Cortinovis, D. L., & Colonese, F. (2023) · Cancers · doi:10.3390/cancers15030689 · Cited by 42
Liquid Biopsies in Lung Cancer
Kemper, M., Krekeler, C., Menck, K., Lenz, G., Evers, G., Schulze, A. B., & Bleckmann, A. (2023) · Cancers · doi:10.3390/cancers15051430 · Cited by 42
Application of radiomics in diagnosis and treatment of lung cancer
Pan, F., Li, F., Liu, B., Hu, Y., & Wang, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1295511 · Cited by 47
Parra, E. R., Zhang, J., Duose, D. Y., Gonzalez‐Kozlova, E., Redman, M. W., Chen, H., Manyam, G. C., Kumar, G., Zhang, J., Song, X., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0251 · Cited by 43
Yin, X., Song, X., Deng, W., BLAKE, N. W., Luo, X., & Meng, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1483454 · Cited by 44
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives
Zhang, H., Pang, Y., Yi, L., Wang, X., Wei, P., Wang, H., & Lin, S. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01856-6 · Cited by 44
Xue, M., Hong, W., Jiang, J. H., Zhao, F., & Gao, X. (2020) · RNA Biology · doi:10.1080/15476286.2020.1789819 · Cited by 42
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
Bomze, D., Asher, N., Ali, O. H., Flatz, L., Azoulay, D., Markel, G., & Meirson, T. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.17675 · Cited by 42
Adeniji, A. A., Dulal, S., & Martin, M. G. (2021) · World Journal of Oncology · doi:10.14740/wjon1345 · Cited by 45
Immunotherapy in Hepatocellular Carcinoma
Fulgenzi, C. A. M., TALBOT, T. L., Murray, S. M., Silletta, M., Vincenzi, B., Cortellini, A., & Pinato, D. J. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00886-5 · Cited by 43
Meng, G., Liu, X., Ma, T., Lv, D., & Sun, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263629 · Cited by 42
Bioinformatics analysis of the circRNA–miRNA–mRNA network for non-small cell lung cancer
Cai, X., Lin, L., Zhang, Q., Wu, W., & Su, A. (2020) · Journal of International Medical Research · doi:10.1177/0300060520929167 · Cited by 41
A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade
Ngoi, N. Y. L., Peng, G., & Yap, T. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-025136 · Cited by 42
Szeto, C. H., Shalata, W., Yakobson, A., & Agbarya, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235614 · Cited by 41
Ulas, E. B., Hashemi, S. M. S., Houda, I., Kaynak, A., Veltman, J. D., Fransen, M. F., Radonic, T. R., & Bahce, I. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100532 · Cited by 41
Guan, W., & Wang, Q. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154938 · Cited by 43
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
Fu, M., Zhao, J., Zhang, L., Sheng, Z., Li, X., Qiu, F., Feng, Y., You, M., Xu, H., Zhang, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.012 · Cited by 41
Wang, C., Li, M., Wei, R., & Wu, J. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100332 · Cited by 41
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
Duchemann, B., Remón, J., Naigeon, M., Mezquita, L., Ferrara, R., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., et al. (2020) · Cancers · doi:10.3390/cancers12123625 · Cited by 42
Man, J., Millican, J., Mulvey, A., Gebski, V., & Hui, R. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab012 · Cited by 40
Tanaka, I., Furukawa, T., & Morise, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02165-7 · Cited by 42
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC
Zhang, F., Wang, J., Xu, Y., Cai, S., Li, T., Wang, G., Li, C., Zhao, L., & Hu, Y. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00243-7 · Cited by 41
Metadata
- Authors
- Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J. R., O’Byrne, K. J., Geese, W. J., Bhagavatheeswaran, P., Rabindran, S. K., Kasinathan, R. S., Nathan, F. E., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Universidad Complutense de Madrid (ES)
- From the Memorial Sloan Kettering Cancer Center, New York (M.D.H.); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A.), Hospital Universitario Virgen Del Rocio, Seville (R.B.C.), and the Catalan Institute of Oncology–Germans Trias i Pujol Hospital, Badalona (E.C.C.) — all in Spain; Ambulatorium Chemioterapii, Bydgoszcz, Poland (B.Z.); the Asan Medical Center (S.-W.K....
- Fox Chase Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-21
- Volume
- 381
- Issue
- 21
- Pages
- 2020-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2976744492
- Cited by
- 2,823
- References
- 26
- Citations by year
- 2026: 183 · 2025: 316 · 2024: 399 · 2023: 448 · 2022: 516 · 2021: 570 · 2020: 368 · 2019: 18
- FWCI
- 154.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- ipilimumab, non-small cell lung cancer, PD-L1 expression, immune checkpoint inhibitors, combination immunotherapy, overall survival, chemotherapy, PD-1, CTLA-4, long-term benefits, PD-L1-negative tumors, stage IV lung cancer, recurrent lung cancer, immune-related adverse events, immune-related pneumonitis
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
